Ordaōs Bio

Ordaōs has unique access to its own Design Engine that uses reinforcement learning to turn human-targeted product criteria into their manufactured mini-proteins, which are more therapeutically effective, cheaper and easier to develop, and less likely to have adverse effects on patients. Branded ‘Ordaōs miniPRO’, these proteins deliver the performance of antibodies but are easier to manage and manipulate, hence are available to use on a wide number of bespoke clients with specific targets.

The industry’s trust in Ordaōs' offerings is marked by significant investments that are going towards maximizing drug candidate delivery speed, novelty and the probability of clinical success.